What is Esperion Therapeutics's accrued liabilities?

Esperion Therapeutics (ESPR) reported accrued liabilities of -$4.86M in Q1 2026.

How has Esperion Therapeutics's accrued liabilities changed year-over-year?

Esperion Therapeutics's accrued liabilities decreased by 421.9% year-over-year, from -$932K to -$4.86M.

What is the long-term trend for Esperion Therapeutics's accrued liabilities?

Over 2 years (2023 to 2025), Esperion Therapeutics's accrued liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $22.1M to $31.22M.

Esperion Therapeutics ESPR Accrued liabilities

Accrued liabilities at other companies

Nektar TherapeuticsNKTR

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's accrued liabilities?: Esperion Therapeutics (ESPR) reported accrued liabilities of -$4.86M in Q1 2026.
How has Esperion Therapeutics's accrued liabilities changed year-over-year?: Esperion Therapeutics's accrued liabilities decreased by 421.9% year-over-year, from -$932K to -$4.86M.
What is the long-term trend for Esperion Therapeutics's accrued liabilities?: Over 2 years (2023 to 2025), Esperion Therapeutics's accrued liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $22.1M to $31.22M.